CareDx
MolDx Backs off Proposed LCD for Solid Organ Allograft Rejection Testing
Medicare administrative contractors plan to propose a new LCD in the coming months. Meanwhile, the existing coverage criteria remains.
360Dx Top 30 Jumps 11 Percent in July
Of the 30 companies in the index, 27 saw their share prices increase, while three saw their stock prices decline.
CareDx Revenues Rise 31 Percent on Test Services, Products; Firm Raises Full-Year Guidance
The company's Q2 revenues rose to $92.3 million from $70.3 million the year before, beating the consensus Wall Street estimate of $67.9 million.
360Dx Top 30 Slides 2 Percent in June
Of the 30 companies in the list, 13 companies saw their share prices rise, while 17 firms saw their stock prices decline.
CareDx Stock Rises as Study Shows Cell-Free DNA's Utility for Kidney Allograft Rejection Detection
The Nature Medicine study illustrated the value of CareDx's AlloSure test for monitoring kidney transplant rejection beyond stand-of-care measures.
Jun 4, 2024
360Dx Top 30 Rises 3 Percent in May
May 1, 2024
360Dx Top 30 Falls 6 Percent in April
May 1, 2024
Craig-Hallum Upgrades CareDx to Buy
Jan 3, 2024
Nov 9, 2023